Page 88 - Read Online

Page 10 of 12 Lorenzin et al. J Transl Genet Genom 2019;3:5. I https://doi.org/10.20517/jtgg.2019.01

and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-13.
53. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, et al. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-
based model of prostate cancer progression. Cancer Res 2011;71:2108-17.
54. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, et al. AR intragenic deletions linked to androgen receptor splice variant expression and
activity in models of prostate cancer progression. Oncogene 2012;31:4759-67.
55. Henzler C, Li Y, Yang R, McBride T, Ho Y, et al. Truncation and constitutive activation of the androgen receptor by diverse genomic
rearrangements in prostate cancer. Nat Commun 2016;7:13668.
56. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene
2014;33:3140-50.
57. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, et al. Expression of androgen receptor splice variants in prostate cancer bone
metastases is associated with castration-resistance and short survival. PLoS One 2011;6:e19059.
58. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in
antiandrogen resistance. Science 2015;349:1351-6.
59. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N
Engl J Med 2014;371:1028-38.
60. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-
resistant prostate cancer. Eur Urol 2015;67:53-60.
61. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection
in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and
enzalutamide. J Clin Oncol 2017;35:2149-56.
62. Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, et al. The Detection of androgen receptor splice variant 7 in plasma-derived exosomal
RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol 2017;71:680-7.
63. Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker
with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016;2:1441-9.
64. Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, et al. Assessment of the validity of nuclear-localized androgen receptor splice
variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer. JAMA Oncol 2018;4:1179-86.
65. To SQ, Kwan EM, Fettke HC, Mant A, Docanto MM, et al. Expression of androgen receptor splice variant 7 or 9 in whole blood does not
predict response to androgen-axis-targeting agents in metastatic castration-resistant prostate cancer. Eur Urol 2018;73:818-21.
66. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-
resistant prostate cancer cell lines. Cancer Res 2013;73:483-9.
67. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, et al. Constitutively active androgen receptor splice variants expressed in
castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107:16759-65.
68. Cai L, Tsai YH, Wang P, Wang J, Li D, et al. ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in
castrate-resistant prostate cancer. Mol Cell 2018;72:341-54.e6.
69. Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, et al. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by
HoxB13. Proc Natl Acad Sci U S A 2018;115:6810-5.
70. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al. Maintenance of intratumoral androgens in metastatic prostate
cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
71. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue
of patients with prostate cancer. Clin Cancer Res 2004;10:7121-6.
72. Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate
cancer. Cell 2013;154:1074-84.
73. Kumar A, Coleman I, Morrissey C, Zhang X, True LD, et al. Substantial interindividual and limited intraindividual genomic diversity
among tumors from men with metastatic prostate cancer. Nat Med 2016;22:369-78.
74. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell
2010;18:11-22.
75. Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in
the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem
2005;280:6511-9.
76. Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, et al. International Union of Pharmacology. LXV. The pharmacology and
classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev
2006;58:782-97.
77. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, et al. Glucocorticoid receptor confers resistance to antiandrogens by
bypassing androgen receptor blockade. Cell 2013;155:1309-22.
78. Sahu B, Laakso M, Pihlajamaa P, Ovaska K, Sinielnikov I, et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding
events in prostate cancer cells. Cancer Res 2013;73:1570-80.
79. Grindstad T, Andersen S, Al-Saad S, Donnem T, Kiselev Y, et al. High progesterone receptor expression in prostate cancer is associated with
clinical failure. PLoS One 2015;10:e0116691.
80. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov
2011;1:466-8.